Editorial
|
|
|
|
|
Third- and fourth-generation oral contraceptives in the hot seat
|
|
|
|
New Products
|
|
|
|
|
Lower cost does not justify taking risks
|
|
|
|
|
|
|
|
|
|
|
|
Warfarin remains the standard therapy
|
|
|
|
|
|
|
|
|
|
A first-choice VEGF inhibitor in case of marked visual loss
|
|
|
|
|
|
|
|
|
|
Hepatotoxic drug; more harms than benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decision to continue or stop treatment should be made on a case-by-case basis
|
|
|
|
Reviews
|
|
|
|
|
Levodopa and ropinirole
|
|
|
|
|
|
|
|
|
|
|
|
Harm-benefit balance changes over time
|
|
|
|
|
|
|
|
|
|
Health benefits, no adverse effects
|
|
|
|
|
|
|
|
|
|
A meta-analysis of individual patient data
|
|
|
|
Outlook
|
|
|
|
|
Political issues and the reality of care
|
|
|
|
|
|
|
|
|
|
A study of nine drug classes
|
|
|
|
|
|